« Media center

Antibody Drug Conjugates : Cerbios joins CMC Biologics and IDT Biologika in their Strategic Collaboration offering a fully integrated service to his partners

Cerbios-Pharma SA

schermata-2016-10-14-alle-09-13-17

COPENHAGEN, Denmark, DESSAU, Germany and LUGANO, Switzerland, October 12, 2016

CMC Biologics A/S, a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika GmbH, a privately-held life-science company with a 95 year history of expertise in research, development and manufacture of biologics for human and animal health, announced the addition of Cerbios-Pharma SA (“Cerbios”) and Oncotec Pharma Produktion GmbH (“Oncotec“) to PROVEO, their strategic collaboration for providing a complete and efficient solution to the market for the process development and manufacture of antibody drug conjugates (ADCs).

07-2016-strategic-alliance-for-adcs